Novel Drug Plus Bevacizumab and Chemo Yields Promising Activity in MSS CRC

News
Article

The DeFianCe trial is using DKN-01 plus bevacizumab and chemotherapy to determine if a clinical benefit would occur in patients with microsatellite stable colorectal adenocarcinoma.

“Subgroup analysis demonstrated the greatest benefit in [patients with] rectal/rectosigmoid junction cancer,” according to Meredith Pelster, MD, MSCI.

“Subgroup analysis demonstrated the greatest benefit in [patients with] rectal/rectosigmoid junction cancer,” according to Meredith Pelster, MD, MSCI.

The use of DKN-01 plus bevacizumab (Avastin) and chemotherapy was well tolerated and produced promising clinical activity as second-line treatment for patients with advanced microsatellite stable (MSS) colorectal adenocarcinoma, according to results from the phase 2 DeFianCe trial (NCT05480306) presented at the 2024 Gastrointestinal Cancer Symposium.

In all efficacy evaluable patients, the objective response rate (ORR) was 30%, the disease control rate (DCR) was 93%, 30% of patients had a partial response (PR), 63% had stable disease, and 8% had progressive disease. The median progression-free survival (PFS) was 6.28 months (95% CI, 5.39-8.64) across all patients. The median PFS was 8.64 months (95% CI, 5.59-not available [NA]) among those with left-sided tumors and 4.75 months (95% CI, 1.87-NA) for those with right-sided tumors. Of note, 9 patients remained on therapy at the time of presentation.

“Subgroup analysis demonstrated the greatest benefit in [patients with] rectal/rectosigmoid junction cancer,” Meredith Pelster, MD, MSCI, associate program director of Gastrointestinal Cancer Research at Sarah Cannon Research Institute, said during the presentation.

DKN-01 is a novel monoclonal antibody of IgG4 that may neutralize DKK1, which is a regulator of the Wnt signaling pathway. In previous studies, the use of DKN-01 in combination with fluorouracil (5-FU) has been shown to improve treatment outcomes, specifically in esophagogastric cancer.

In part A of the trial, 33 patients were enrolled, with 25 patients having tumors in the left colon and 8 having tumors in the right colon. Of those with tumors in the left colon, 15 were rectal/rectal sigmoid, and 10 were descending colon/sigmoid.

Patients were eligible for treatment if they had previous treatment with 5-FU, RECIST v1.1 measurable disease, and MSS disease without a BRAFV600 mutation. The data cutoff was December 6, 2023.

After part A, a safety review was conducted. Part B is currently enrolling with an estimated population of 130 patients. Patients will be randomly assigned 1:1 to either the DKN-01 plus bevacizumab and chemotherapy arm (n = 65) or the chemotherapy plus bevacizumab arm (n = 65).

Of the patients enrolled in part A, 60.6% were male, the median age was 56.0 years, and 75.8% of patients had left-sided tumors. A majority of patients had an ECOG performance status of 0 (54.5%), 69.7% had liver metastases, and 100% received prior treatment with 5-FU. When genetics were considered, 75.0% of patients had a KRAS mutation, and 91.7% had APC mutations.

ORR was analyzed between the left-sided and right-sided colon, with rates of 33% vs 17%, respectively. The DCR was 100% vs 67%, the PR rate was 33% vs 17%, the stable disease rate was 67% vs 50%, and progressive disease was seen in 0% vs 33% between the left-sided and right-sided colon, respectively. Rectal tumors were also observed for a response with an ORR of 46%, a DCR of 100%, PRs in 46%, stable disease in 54%, and progressive disease in 0%.

The median PFS for patients with rectal tumors was 9.43 months (95% CI, 3.84-NA). The 6-month PFS rate was 57.1%. At the time of the presentation, 6 patients remained on therapy.

A PR occurred in 6 patients who showed high DKN-01 expression, and 7 patients had stable disease. Plasma levels were investigated using the SomaScan platform.

Grade 3 or higher adverse effects (AEs) were observed in 63.6% of patients, 21.2% had serious AEs, and 9.1% of patients died. With respect to AEs relating to DKN-01, grade 3 or higher toxicity occurred in 27.3% of patients, serious AEs in 3.0%, and deaths in 3.0%. AEs leading to DKN-01 dose reduction and discontinuation, respectively, were observed in 6.1% and 3.0%.

Some of the most common AEs reported were diarrhea, fatigue, neutropenia/neutrophil count decrease, nausea, and constipation.

Reference

Pelster M, Strickler JH, Sirad CA, et al. DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial. J Clin Oncol. 2024;42(suppl 3):104. doi:10.1200/JCO.2024.42.3_suppl.104

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
Related Content